200 related articles for article (PubMed ID: 29475913)
1. Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.
Constantinou C; Papadopoulos S; Karyda E; Alexopoulos A; Agnanti N; Batistatou A; Harisis H
In Vivo; 2018; 32(2):303-311. PubMed ID: 29475913
[TBL] [Abstract][Full Text] [Related]
2. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
3. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
5. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.
Beg S; Siraj AK; Prabhakaran S; Jehan Z; Ajarim D; Al-Dayel F; Tulbah A; Al-Kuraya KS
Breast Cancer Res Treat; 2015 Jun; 151(3):541-53. PubMed ID: 25981902
[TBL] [Abstract][Full Text] [Related]
6. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
Reyes C; Jorda M; Gomez-Fernández C
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826
[TBL] [Abstract][Full Text] [Related]
7. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
8. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.
Inanc M; Ozkan M; Karaca H; Berk V; Bozkurt O; Duran AO; Ozaslan E; Akgun H; Tekelioglu F; Elmali F
Med Oncol; 2014 Jan; 31(1):801. PubMed ID: 24326984
[TBL] [Abstract][Full Text] [Related]
10. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.
Liu ZB; Wu J; Ping B; Feng LQ; Di GH; Lu JS; Shen KW; Shen ZZ; Shaol ZM
Tumori; 2009; 95(1):53-62. PubMed ID: 19366057
[TBL] [Abstract][Full Text] [Related]
11. Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?
Schmidt G; Solomayer EF; Bohle RM; Gerlinger C; Radosa JC; Endrikat J; Kasoha M
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2109-2116. PubMed ID: 32266539
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
16. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters.
Jasar D; Smichkoska S; Kubelka K; Filipovski V; Petrushevska G
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):69-79. PubMed ID: 26076776
[TBL] [Abstract][Full Text] [Related]
18. p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
Coates PJ; Nenutil R; Holcakova J; Nekulova M; Podhorec J; Svoboda M; Vojtesek B
Virchows Arch; 2018 Mar; 472(3):351-359. PubMed ID: 29484502
[TBL] [Abstract][Full Text] [Related]
19. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of basal cytokeratin expression in breast cancer.
Alshareeda AT; Soria D; Garibaldi JM; Rakha E; Nolan C; Ellis IO; Green AR
Breast Cancer Res Treat; 2013 May; 139(1):23-37. PubMed ID: 23588953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
